3,7,8,2'-Tetrahydroxyflavone
3,7-Dihydroxyflavone
4'-Dimethylamino-7,8-dihydroxyflavone
7,3′-Dihydroxyflavone
7,8,2'-Trihydroxyflavone
7,8,3'-Trihydroxyflavone
7,8-Dihydroxyflavone
ABT-110
ALE-0540
AM7 (drug)
AMG-458
ANA-12
ANXA2
ASP-6294
ATC code L01
AVE-1642
AZD-6918
Abemaciclib
Acalabrutinib
Acne vulgaris
Adagrasib
Adenocarcinoma
Adenosine triphosphate
Adipotide
Adrenomedullin
Adverse drug reaction
Afatinib
Aflibercept
Agerafenib
Alacizumab pegol
Alectinib
Alemtuzumab
Alexion Pharmaceuticals
Alpelisib
Altiratinib
American Society of Health-System Pharmacists
Amitriptyline
Amivantamab
Amphiregulin
Amuvatinib
Anaplastic lymphoma kinase
Anastrozole
Anatomical Therapeutic Chemical Classification System
Ancestim
Andexanet alfa
Angiopoietin 1
Angiopoietin 2
Angiopoietin 3
Angiopoietin 4
Angiopoietin receptor
Anifrolumab
Anorexia (symptom)
Anti-apoptotic Ras signalling cascade
Antineoplastic
Aprutumab
Aprutumab ixadotin
Artemin
Asciminib
Asfotase alfa
Asthenia
AstraZeneca
Astra AB
Atenolol
Atezolizumab
Atezolizumab/hyaluronidase
Aumolertinib
Australian Medicines Handbook
Avapritinib
Avelumab
Axatilimab
Axitinib
Axokine
BBC
BMS-754807
BMS-777607
BNN-20
BNN-27
BRAF (gene)
Baricitinib
Bcr-abl fusion protein
Becaplermin
Belantamab mafodotin
Benralizumab
Bermekimab
Betacellulin
Bevacizumab
Bibcode (identifier)
Bicalutamide
Binimetinib
Bioavailability
Biological half-life
Blepharitis
Blinatumomab
Bosutinib
Brain-derived neurotrophic factor
Brentuximab vedotin
Brigatinib
Brompheniramine
Bruton's tyrosine kinase
Budesonide
Budesonide/formoterol
Budesonide/glycopyrronium bromide/formoterol
Burosumab
C-Met
CAS Registry Number
CD117
CD135
CD20
CD30
CD33
CD3 (immunology)
CD52
CDK inhibitor
CE-245677
CH-7057288
CSPG5
CYP3A4
Cabozantinib
Cambridge Antibody Technology
Cancer immunotherapy
Cancers
Candesartan
Canertinib
Capmatinib
Carcinoma
Catumaxomab
Cediranib
Cemiplimab
Cenegermin
Cerebrolysin
Ceritinib
Cetuximab
ChEBI
ChEMBL
ChemSpider
Chemical formula
Ciliary neurotrophic factor receptor
Cixutumumab
Clinical trial
Cobimetinib
Colony-stimulating factor
CompTox Chemicals Dashboard
Conjunctivitis
Connective tissue growth factor
Copanlisib
Cornea
Cosibelimab
Covalent bond
Crenolanib
Crizotinib
Cyclotraxin B
Cytotoxic
DMAQ-B1
DS-6051
Dabrafenib
Dacomitinib
DailyMed
Dalotuzumab
Dalpiciclib
Dapagliflozin
Dapiclermin
Daratumumab
Dasatinib
Dehydration
Dehydroepiandrosterone
Dehydroepiandrosterone sulfate
Denileukin diftitox
Deoxygedunin
Depatuxizumab
Depatuxizumab mafodotin
Deprenyl
Des(1-3)IGF-1
Dexamethasone
Diarrhoea
Dihexa
Dinutuximab beta
Diosmetin
Disufenton sodium
Doi (identifier)
Dostarlimab
DrugBank
Drug metabolism
Drug nomenclature
Drugs.com
Duligotumab
Durvalumab
Dusigitumab
Duvelisib
ECHA InfoCard
EFNA1
EFNA2
EFNA3
EFNA4
EFNA5
EFNB1
EFNB2
EFNB3
EGFR inhibitor
EML4
EVT-901
Ectopic pregnancy
Eculizumab
Edinburgh
Edrecolomab
Elotuzumab
Elranatamab
Emibetuzumab
Encorafenib
Enfortumab vedotin
Entrectinib
EpCAM
Epcoritamab
Ephrin
Epidermal growth factor
Epidermal growth factor receptor
Epigen
Epiregulin
ErbB
Erdafitinib
Erlotinib
Ersofermin
Ertumaxomab
Erythropoietin
Esomeprazole
European Medicines Agency
Everolimus
Evinacumab
Excretion
Exenatide
Exotoxin
FGF1
FGF10
FGF15/19
FGF17
FGF18
FGF19
FGF2
FGF20
FGF22
FGF23
FGF3
FGF4
FGF5
FGF6
FGF7
FGF8
FGF9
FX007
Fasinumab
Fedratinib
Fibroblast growth factor
Fibroblast growth factor receptor
Fibroblast growth factor receptor 1
Fibroblast growth factor receptor 2
Fibroblast growth factor receptor 3
Fibroblast growth factor receptor 4
Ficlatuzumab
Figitumumab
Filgotinib
First-line treatment
Flanvotumab
Food and Drug Administration
Foretinib
Fosgonimeton
Frunevetmab
Fruquintinib
Fulranumab
Fulvestrant
Fusion protein
Futibatinib
Futuximab
GBR-900
GFRα1
GFRα2
GFRα3
GFRα4
GZ-389988
Gambogic amide
Ganitumab
Gefitinib (data page)
Gemtuzumab ozogamicin
Generic medication
Gilteritinib
Glasdegib
Glia maturation factor
Glial cell line-derived neurotrophic factor
Glofitamab
Glucose-6-phosphate isomerase
Glycopyrronium bromide/formoterol
Glypromate
Golvatinib
Goserelin
Gossypetin
Grandinin
Growth factor receptor
Guide to Pharmacology
HER2/neu
HER3
HER4
HIOC
Hdl (identifier)
Health Canada
Hedgehog signaling pathway
Heparin-binding EGF-like growth factor
Hepatocyte growth factor
Hepatocyte growth factor receptor
Hepatoma-derived growth factor
IGF-1 LR3
IGFBP1
IGFBP2
IGFBP3
IGFBP4
IGFBP5
IGFBP6
IGFBP7
INCB28060
ISBN (identifier)
IUPAC nomenclature of chemistry
Ibritumomab tiuxetan
Ibrutinib
Icotinib
Icrucumab
Idelalisib
Imatinib
Imgatuzumab
Inavolisib
Infigratinib
Inotuzumab ozogamicin
Insulin
Insulin-like growth factor-binding protein
Insulin-like growth factor 1
Insulin-like growth factor 1 receptor
Insulin-like growth factor 2
Insulin-like growth factor 2 receptor
Interleukin
Interleukin 2
International Chemical Identifier
Interstitial lung disease
Ipilimumab
Iressa (moth)
Isatuximab
Isosorbide mononitrate
JNJ-38877605
JSmol
Janus kinase
K252a
KEGG
KRAS
Keratinocyte growth factor
LEVI-04
LM22A-4
Lapatinib
Larotrectinib
Lazertinib
Lenvatinib
Lestaurtinib
Leukemia
Leukemia inhibitory factor
Liatermin
Linsitinib
Live attenuated influenza vaccine
Liver
Liver enzyme
Loncastuximab tesirine
Lorlatinib
Louis Schweitzer (CEO)
Low-affinity nerve growth factor receptor
Lymphatic system
Lymphoma
MEDI-578
MEN1
MK-2461
MTOR inhibitor
Macrophage-stimulating protein
Masitinib
Matuzumab
Mecasermin
Mecasermin rinfabate
MedImmune
Medication
MedlinePlus
Melbourne
Methotrexate
Metoprolol
Midkine
Midostaurin
Migration-stimulating factor
Milciclib
Mirvetuximab soravtansine
Mitogen-activated protein kinase kinase
Mobocertinib
Mogamulizumab
Molar mass
Momelotinib
Monoclonal antibody therapy
Mosunetuzumab
Motavizumab
Motesanib
Moxetumomab pasudotox
Mubritinib
Murodermin
Myeloid
N-Acetylserotonin
NRG2
NRG3
NRG4
NVP-ADW742
NVP-AEW541
Naxitamab
Necitumumab
Nepidermin
Neratinib
Nerve growth factor
Nesvacumab
Neuregulin
Neuregulin-1
Neurotrophin-3
Neurotrophin-4
Neurturin
Nilotinib
Nimotuzumab
Nintedanib
Nivolumab
Non-receptor tyrosine kinase
Non-small cell lung cancer
Norwogonin
ONO-4474
ONO-5390556
OSl-906
Obinutuzumab
Odronextamab
Ofatumumab
Olaparib
Olaratumab
Olmutinib
Omeprazole
Onartuzumab
Oncomodulin
Oportuzumab monatox
Oral administration
Orelabrutinib
Osimertinib
Oxford–AstraZeneca COVID-19 vaccine
PDGFA
PDGFB
PDGFC
PDGFD
PF-04217903
PF-2341066
PHA-665752
PLX-7486
PMC (identifier)
PMID (identifier)
Pacritinib
Palbociclib
Palifermin
Palivizumab
Panitumumab
Paronychia
Parsaclisib
Patritumab
Pazopanib
Pegaptanib
Pembrolizumab
Pemigatinib
Persephin
Pertuzumab
Pexidartinib
Pharmacokinetics
Pi3K inhibitor
Pirtobrutinib
Pituitary adenylate cyclase-activating peptide
Placental growth factor
Plasma protein binding
Platelet-derived growth factor
Platelet-derived growth factor receptor
Pleiotrophin
Polatuzumab vedotin
Ponatinib
Pralsetinib
Pregnancy category
Prescription drug
Proapoptotic
Progression-free survival
Prohibitin
Prolgolimab
Propofol
PubChem
Quetiapine
Quizartinib
R13 (drug)
R1507
R7 (drug)
RBM-004
RET proto-oncogene
RTK class III
Radotinib
Ramucirumab
Ranevetmab
Ranibizumab